Gilead Sciences Chairman & CEO Daniel O'Day Sells $2.22M in Common Stock Under Rule 10b5-1 Plan

Executive Summary

On October 1, 2026, Daniel Patrick O'Day, Chairman and Chief Executive Officer of Gilead Sciences, Inc. ($GILD), executed sales of 15,000 shares of Common Stock across two tranches for a combined value of approximately $2,218,508. Following the transactions, Mr. O'Day directly holds 566,683 shares.

Transaction Details

• Tranche 1: 12,000 shares sold at a weighted average price of $147.719 (ranging from $147.21 to $148.205).
• Tranche 2: 3,000 shares sold at a weighted average price of $148.6265 (ranging from $148.23 to $149.13).
• Total Shares Sold: 15,000
• Effective Average Price: ~$147.90 per share
• Total Gross Proceeds: $2,218,507.50
• Post-Transaction Direct Ownership: 566,683 shares

Key Context and Governance

• Rule 10b5-1 Trading Plan: The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on February 25, 2026. Such plans allow insiders to establish automated selling schedules, mitigating concerns of trading on material non-public information.
• Ownership Impact: The disposition represents approximately 2.58% of his holdings prior to the transactions, leaving him with a substantial direct stake of over 566,000 shares.
• Market Significance: Assessed as Low due to the pre-scheduled nature under Rule 10b5-1 and the modest fraction of the insider's total equity position being divested.